Techniques have been intensified and developed in the last few years by directly or indirectly targeting cdks and these have been evaluated extensively. Natura alpha inhibited the growth of both androgen dependent, and androgen independent prostate cancer cells with IC50 between 4 to 10 Um, also stops invasion of androgen independent prostate cancer cells. Its anti tumor effects were further evident in vivo tumor lowering of androgen dependent and independent naked rats tumor xenograft models in addition to decreased Docetaxel molecular weight tumor volume in the in-patient with hormone refractory metastatic prostate cancer. PPAA revealed that anti and antiproliferative invasive activities of Natura alpha on prostate cancer may largely be through its down-regulation of Forkhead package M1 protein. Forced overexpression of FOXM1 largely reversed the inhibition by Natura alpha. Prostate cancer may be the most frequent cancer in men in america, and was likely to cause 27,360 deaths and 192,280 new cases in ’09. Androgen ablation is the most typical treatment for advanced prostate cancer. The treatment failure of prostate cancer lies in the fact, after androgen ablation therapy, the disease inevitably advances from androgen reliance to androgen locomotor system independence. For individuals who are not cured by local treatment with ensuing metastasizes, neither androgen ablation nor chemotherapy can increase their survival time. Ergo, the development of new powerful therapeutic agents with minimal negative effects is highly warranted. Cancer is increasingly being regarded as a cell cycle condition since deregulation in the cell cycle machinery is found in most cancers. Major factors in the cell-cycle machinery are cyclin dependent kinases and their interacting associates, the cyclins and the endogenous inhibitors. Defects have already been described in the components of the cell cycle machinery it self, or the chk inhibitor check-point components that ensure orderly advancement through the cell cycle stages, or in upstream signaling that triggers cell cycle events. The first two cdk inhibitors, Flavopiridol and UCN 01 have been in clinical trials alone, or in mixture with other chemotherapeutic agents, and have shown promising with proof antitumor activity. Indirubin, a dynamic chemical identified in the standard Chinese herbal medicine Qing Dai, continues to be used to treat leukemia for many years. Recently, there’s been a remarkable revival of the fascination with indirubin due to the discovery of its great pharmacological potential. Growing evidences show that indirubin, and its derivatives and analogues, target different crucial signal pathways involved in cancer, including inhibition of cyclin dependent kinases.